A phase I/II study of immunotherapy with hLL1 administered twice weekly for 4 consecutive weeks in patients with, multiple myeloma.
Phase of Trial: Phase I/II
Latest Information Update: 21 Mar 2012
At a glance
- Drugs Milatuzumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Immunomedics
- 21 Mar 2012 Actual patient number is 25 according to ClinicalTrials.gov.
- 21 Mar 2012 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.